Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Mean dose to the tongue mucosa did not improve predictions of taste impairment during and after radiation therapy compared ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Head and neck cancer is diagnosed in at least 700,000 patients each year. A team of 27 doctors has found a comforting means ...

Oropharyngeal cancer, or throat cancer, is a type of head and neck cancer that can be divided into two subgroups: ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Professor and surgeon Jason Hunt, MD, MS, FACS, has been named inaugural Chair of the Department of Otolaryngology – Head and ...